Oncology Venture: Publication of supplement to prospectus
Oncology Venture Sweden AB ("Oncology Venture") hereby publish a supplement to the prospectus due to the press release the company published on January 8th, 2018, which was published after the approval of the company's prospectus by the Swedish Financial Supervisory Authority prior to Oncology Venture's rights issue with subscription period on January 11th - January 25th, 2018. The supplement to the prospectus is available on the company's (www.oncologyventure.com), Sedermera Fondkommission's (www.sedermera.se) and AktieTorget's (www.aktietorget.se) respective websites.
"Oncology Venture AB was formed in 2012 by Danish and US oncology specialists and business people dedicated to unlock the potential of oncology products that has shown efficacy but not enough to beat the gold standard - to improve the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines and through this improve success rates in Oncology Drug Development."Venlighedsvej 1,
DK-2970 HOERSHOLM, Danmark +45 21 70 10 49 http://www.oncologyventure.com